231 related articles for article (PubMed ID: 33290964)
1. JAK2 expression is correlated with the molecular and clinical features of breast cancer as a favorable prognostic factor.
Liu Q; Ai B; Kong X; Wang X; Qi Y; Wang Z; Fang Y; Wang J
Int Immunopharmacol; 2021 Jan; 90():107186. PubMed ID: 33290964
[TBL] [Abstract][Full Text] [Related]
2. Molecular and Clinical Characterization of PD-1 in Breast Cancer Using Large-Scale Transcriptome Data.
Liu Q; Cheng R; Kong X; Wang Z; Fang Y; Wang J
Front Immunol; 2020; 11():558757. PubMed ID: 33329517
[TBL] [Abstract][Full Text] [Related]
3. TIGIT-related transcriptome profile and its association with tumor immune microenvironment in breast cancer.
Zhang Q; Gao C; Shao J; Wang Z
Biosci Rep; 2021 Mar; 41(3):. PubMed ID: 33721026
[TBL] [Abstract][Full Text] [Related]
4. The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.
Xie X; Zhang J; Shi Z; Liu W; Hu X; Qie C; Chen W; Wang Y; Wang L; Jiang J; Liu J
Front Immunol; 2020; 11():563044. PubMed ID: 33250890
[TBL] [Abstract][Full Text] [Related]
5. CD2 Is a Novel Immune-Related Prognostic Biomarker of Invasive Breast Carcinoma That Modulates the Tumor Microenvironment.
Chen Y; Meng Z; Zhang L; Liu F
Front Immunol; 2021; 12():664845. PubMed ID: 33968066
[TBL] [Abstract][Full Text] [Related]
6. High Expression of microRNA-143 is Associated with Favorable Tumor Immune Microenvironment and Better Survival in Estrogen Receptor Positive Breast Cancer.
Tokumaru Y; Asaoka M; Oshi M; Katsuta E; Yan L; Narayanan S; Sugito N; Matsuhashi N; Futamura M; Akao Y; Yoshida K; Takabe K
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32370060
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Transcriptomic Analysis Reveals the Role of the Immune Checkpoint HLA-G Molecule in Cancers.
Xu HH; Gan J; Xu DP; Li L; Yan WH
Front Immunol; 2021; 12():614773. PubMed ID: 34276642
[TBL] [Abstract][Full Text] [Related]
8. A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint.
Zhou X; Du J; Liu C; Zeng H; Chen Y; Liu L; Wu D
Front Immunol; 2021; 12():688215. PubMed ID: 34305920
[TBL] [Abstract][Full Text] [Related]
9. Immune-related gene data-based molecular subtyping related to the prognosis of breast cancer patients.
Mu G; Ji H; He H; Wang H
Breast Cancer; 2021 Mar; 28(2):513-526. PubMed ID: 33245478
[TBL] [Abstract][Full Text] [Related]
10. Identification of DRP1 as a prognostic factor correlated with immune infiltration in breast cancer.
Liu B; Fan Y; Song Z; Han B; Meng Y; Cao P; Tan K
Int Immunopharmacol; 2020 Dec; 89(Pt B):107078. PubMed ID: 33049497
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.
Ikeda S; Okamoto T; Okano S; Umemoto Y; Tagawa T; Morodomi Y; Kohno M; Shimamatsu S; Kitahara H; Suzuki Y; Fujishita T; Maehara Y
J Thorac Oncol; 2016 Jan; 11(1):62-71. PubMed ID: 26762740
[TBL] [Abstract][Full Text] [Related]
12. Eight immune-related genes predict survival outcomes and immune characteristics in breast cancer.
Xu H; Wang G; Zhu L; Liu H; Li B
Aging (Albany NY); 2020 Aug; 12(16):16491-16513. PubMed ID: 32756008
[TBL] [Abstract][Full Text] [Related]
13. Exploring GZMK as a prognostic marker and predictor of immunotherapy response in breast cancer: unveiling novel insights into treatment outcomes.
Li Z; Xie Q; Zhao F; Huo X; Ren D; Liu Z; Zhou X; Shen G; Zhao J
J Cancer Res Clin Oncol; 2024 Jun; 150(6):286. PubMed ID: 38833021
[TBL] [Abstract][Full Text] [Related]
14. Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Jul; 8(29):47400-47411. PubMed ID: 28537889
[TBL] [Abstract][Full Text] [Related]
15. Identification of Genes with Prognostic Value in the Breast Cancer Microenvironment Using Bioinformatics Analysis.
Ren H; Hu D; Mao Y; Su X
Med Sci Monit; 2020 Apr; 26():e920212. PubMed ID: 32251269
[TBL] [Abstract][Full Text] [Related]
16. MS4A1 as a Potential Independent Prognostic Factor of Breast Cancer Related to Lipid Metabolism and Immune Microenvironment Based on TCGA Database Analysis.
Li S; Fang Y
Med Sci Monit; 2022 Jan; 28():e934597. PubMed ID: 35091527
[TBL] [Abstract][Full Text] [Related]
17. A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome.
Hachim IY; Shams A; Lebrun JJ; Ali S
Hum Pathol; 2016 Jul; 53():142-52. PubMed ID: 26980025
[TBL] [Abstract][Full Text] [Related]
18. Reduced mRNA expression levels of NFE2L2 are associated with poor outcome in breast cancer patients.
Wolf B; Goebel G; Hackl H; Fiegl H
BMC Cancer; 2016 Oct; 16(1):821. PubMed ID: 27770790
[TBL] [Abstract][Full Text] [Related]
19. Identification of the GTPase IMAP family as an immune-related prognostic biomarker in the breast cancer tumor microenvironment.
Huo X; Shen G; Li J; Wang M; Xie Q; Zhao F; Ren D; Dong Q; Zhao J
Gene; 2022 Feb; 812():146094. PubMed ID: 34896519
[TBL] [Abstract][Full Text] [Related]
20. The Immune Profile of Pituitary Adenomas and a Novel Immune Classification for Predicting Immunotherapy Responsiveness.
Wang Z; Guo X; Gao L; Deng K; Lian W; Bao X; Feng M; Duan L; Zhu H; Xing B
J Clin Endocrinol Metab; 2020 Sep; 105(9):e3207-23. PubMed ID: 32652004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
